Thoratec Corporation

Skip to content

2014 Press Releases

Keyword Search

2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
10/15/14Thoratec Schedules Third Quarter Conference Call, Webcast
PLEASANTON, Calif., Oct. 15, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter of fiscal year 2014 on Wednesday, November 5. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Standard Time ... 
Printer Friendly Version
10/06/14Thoratec Announces Additions To Senior Management Team
PLEASANTON, Calif., Oct. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that Niamh Pellegrini has joined Thoratec in the new role of President, North America.     This new position at Thoratec encompasses responsibility for all commercial operations within North America.  Ms. Pellegrini has over twenty-five years of experience in the healthcare ind... 
Printer Friendly Version
09/22/14Thoratec Appoints D. Keith Grossman President And Chief Executive Officer
COMPANY PROVIDES THIRD QUARTER FINANCIAL UPDATES PLEASANTON, Calif., Sept. 22, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that D. Keith Grossman has been appointed President and Chief Executive Officer, effective immediately.  Mr. Grossman succeeds Gary F. Burbach, who has stepped down from his executive and Board roles but will remain as an advis... 
Printer Friendly Version
09/09/14Thoratec Announces Start Of Heartmate III™ U.S. Clinical Trial
PLEASANTON, Calif., Sept. 9, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun to enroll patients in the HeartMate III™ U.S. clinical trial.  "We are excited to continue our recent pipeline progress with the start of the U.S. clinical trial for HeartMate III," said Gary F. Burbach, President and Chief Executive Officer.  "Our innovativ... 
Printer Friendly Version
08/29/14Thoratec Presentation At Morgan Stanley Healthcare Conference To Be Webcast
PLEASANTON, Calif., Aug. 29, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 12:55 p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Ti... 
Printer Friendly Version
08/06/14Thoratec® Reports Second Quarter 2014 Results
- Revenue of $118.1 million for the second quarter of 2014 - GAAP Net Income per Diluted Share of $0.30, and Non-GAAP Net Income per Diluted Share of $0.43 - Company adjusts full-year 2014 guidance for revenue to a range of $455 million to $470 million and for net income per diluted share to $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis - HeartMate III™ and HeartMate PHP™ begin CE Mark Trials; FDA grants conditional approval to start HeartMate III U.S. IDE trial ... 
Printer Friendly Version
08/06/14Thoratec Announces $30 Million Accelerated Share Repurchase
PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has entered into a $30 million Accelerated Share Repurchase (ASR) agreement. "This commitment to capital deployment reflects our ongoing conviction in the long term opportunities in our business," said Gary F. Burbach, President and Chief Executive Officer.  "Furthermore, o... 
Printer Friendly Version
08/06/14Thoratec Announces Start Of The HeartMate PHP™ CE Mark Trial
PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its CE Mark Clinical Trial for HeartMate PHPTM (Percutaneous Heart Pump) has commenced. "We are excited to begin the CE Mark Clinical Trial for HeartMate PHP and look forward to successful execution of this important clinical study," said Gary F. Burbach, President and Chief Executive... 
Printer Friendly Version
08/04/14Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast
PLEASANTON, Calif., Aug. 4, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 2:00 p.m., Eastern Daylight Time (11:00 a.m., Pacific Daylight T... 
Printer Friendly Version
07/21/14Thoratec Schedules Second Quarter Conference Call, Webcast
PLEASANTON, Calif., July 21, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the second quarter of fiscal year 2014 on Wednesday, August 6. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (... 
Printer Friendly Version
07/02/14Thoratec Acquires Apica Cardiovascular
PLEASANTON, Calif., July 2, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has acquired Apica Cardiovascular Limited ("Apica") for an upfront cash payment of $35 million and potential future clinical and sales milestones of up to $40 million.  As part of the agreement, the Apica team based at facilities in Ireland and the United States will transition... 
Printer Friendly Version
06/27/14Thoratec Announces First HeartMate III™ Human Implant And Start Of CE Mark Trial
PLEASANTON, Calif., June 27, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE Mark Clinical Trial for HeartMate III™ commenced with the first patient implanted with this new device. "We are pleased to reach this significant clinical milestone with an important pipeline product," said Gary F. Burbach, President and Chief Executive Officer.  "We a... 
Printer Friendly Version
06/03/14Thoratec Announces Presentations At Investor Conferences For June 2014
PLEASANTON, Calif., June 3, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in three upcoming investor conferences. On Tuesday, June 10, the company will participate in the Goldman Sachs 35th Annual Global Healthcare Conference.  Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning... 
Printer Friendly Version
05/06/14Thoratec® Reports First Quarter 2014 Results
-Revenue of $125.7 million for the first quarter of 2014 -GAAP net income per diluted share of $0.32, and non-GAAP income per net diluted share of $0.41 -Company reiterates 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis PLEASANTON, Calif., May 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies... 
Printer Friendly Version
04/30/14Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast
PLEASANTON, Cailf., April 30, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Bank of America Merrill Lynch 2014 Healthcare Conference on Tuesday, May 13. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 3:00 p.m., Pacific Daylight Time (6:00 p.m., Eastern Daylight Ti... 
Printer Friendly Version
04/14/14Thoratec Schedules First Quarter Conference Call, Webcast
PLEASANTON, Calif., April 14, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2014 on Tuesday, May 6. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ... 
Printer Friendly Version
02/26/14Thoratec Announces Presentations At Investor Conferences For March 2014
PLEASANTON, Calif., Feb. 26, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Monday, March 3, the company will participate in the Raymond James 35th Annual Institutional Investors Conference. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, ... 
Printer Friendly Version
02/04/14Thoratec® Reports Fourth Quarter 2013 Results
- Revenue of $128.2 million for the fourth quarter of 2013 - GAAP net income per diluted share of $0.23, and non-GAAP net income per diluted share of $0.38 - Company establishes 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis PLEASANTON, Calif., Feb. 4, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory sup... 
Printer Friendly Version
01/31/14Thoratec Presentation At Leerink Global Healthcare Conference To Be Webcast
PLEASANTON, Calif., Jan. 31, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Leerink Global Healthcare Conference on Wednesday, February 12. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 3:05 p.m., Eastern Standard Time (12:05 p.m., Pacific Standard Time).  ... 
Printer Friendly Version
01/23/14Thoratec Schedules Fourth Quarter Conference Call, Webcast
PLEASANTON, Calif., Jan. 23, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the fourth quarter of fiscal year 2013 on Tuesday, February 4. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Standard Time (... 
Printer Friendly Version